Federal regulators approved Amgen Inc.’s anti-osteoporosis drug, Prolia, on Tuesday for use by postmenopausal women who face a high risk of bone fractures.
One of every two women over the age of 50 will break a bone in their lifetimes because of osteoporosis, which causes bones to become brittle, the Food and Drug Administration said in a statement announcing its move.
[LA Times]